Moringa Powder Acceptability Trial Among Healthy Adults

Status Active, not recruiting

Clinical Trial Summary

The study is a randomized acceptability trial involving the provision of three different doses of Moringa powder to be consumed daily by study participants.

Clinical Trial Description

Moringa is a drought-resistant nutrient-dense tree with high concentrations of anti-inflammatory plant chemicals in its edible leaves and seeds. In preclinical studies Moringa has been shown to improve insulin resistance, dyslipidemia, and high blood pressure. But its effects in humans remain unclear. Moringa (20g leaf powder on two different days) supplementation decreased post-prandial glucose in Saharawi refugees with type 2 diabetes, compared to controls (Leone, et. al., 2018). In a randomized control trial in Spain, Moringa consumed as six daily capsules of dry leaf powder (2.4 g/day) for 12 weeks, significant decreased fasting blood glucose and glycated hemoglobin (HbA1c) among prediabetic subjects (Gomez-Martinez, et. al., 2021). The investigators are conducting a testing trial of Moringa oleifera leaves, offered as powder, to be added to foods and/or drinks to test safety, acceptability and consumption of it in three different doses: 1 tsp, 2 tsp, and 3 tsp. Study participants will be randomly allocated to one of the three doses. Among the studies that have been conducted with human subjects (individuals with diabetes), no adverse effects have been reported with whole leaf powder at up to a single dose of 50 g or using 8 g per day dose for 40 days (Stohs & Hartman, 2015). The outcomes to be measured in this testing trial are the following: - Consumption (measured by self-report and skin carotenoid level, as a biomarker of consumption of fruits and vegetables) - Acceptability (measured by rating the taste of the moringa powder when consumed with foods/drinks) - Safety (measured by self-report of any potential side effects, such as digestive issues due to fiber content) Results from this trial will suggest an acceptable dose in a population not yet diagnosed with a specific disease (e.g. diabetes) and therefore potentially less willing to consume it in doses that could make taste a potential barrier for consumption. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05861076
Study type	Interventional
Source	University of California, Berkeley
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 3, 2023
Completion date	May 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06309641` - Methemoglobinemia Following Intravenous Iron Treatment
Completed	`NCT04256590` - Tongue Depressor-related Tongue Swelling
Completed	`NCT04543851` - CARA Treatment Pilot Study for Breast Positioning	N/A
Completed	`NCT04205253` - Tongue Depressor-related Ischemia-Reperfusion Injury in Tongue
Completed	`NCT06133218` - Patient Reported Outcomes Using Mepitel Film During Radiotherapy	N/A
Active, not recruiting	`NCT05155202` - Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
Not yet recruiting	`NCT06060886` - Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis	Phase 4
Recruiting	`NCT05055648` - PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy	N/A
Completed	`NCT02146053` - Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron.	Early Phase 1
Completed	`NCT02978846` - Perceptions of Side Effects of Cancer Chemoradiotherapy
Completed	`NCT03949270` - Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer	N/A
Recruiting	`NCT05958823` - Effects of Serratus Anterior Plan Block (SAP) and Pectoralis Blocks (PECS I-II) After Open Heart Surgery	N/A
Recruiting	`NCT04506840` - Physical Activity and Motivation in Colorectal Cancer Patients	N/A
Completed	`NCT05421962` - Analgosedation for Elective Colonoscopy	Phase 1
Completed	`NCT04456621` - Proton Beam Therapy for Unresectable Liver Metastasis	N/A
Not yet recruiting	`NCT04066998` - Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab	N/A
Completed	`NCT03530787` - Cosmetic Effects of Topical Acetyl Zingerone	N/A
Completed	`NCT03684993` - Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients	Phase 2/Phase 3
Completed	`NCT04066153` - Patient Reported Unmet Needs for Function and Supportive Occupational- and Physiotherapy Rehabilitation Interventions
Completed	`NCT05542849` - The Efficacy and Tolerability of Acarbose in Healthy Individuals	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.